Arvinas Inc (OQ:ARVN)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 5 Science Park
NEW HAVEN CT 06511-1966
Tel: N/A
Website: https://www.arvinas.com
IR: See website
<
Key People
John G. Houston
Chairman of the Board, President, Chief Executive Officer
Randy Teel
Interim Chief Financial Officer, Treasurer
Ian Taylor
Chief Scientific Officer
Jared Morris Freedberg
General Counsel
Noah Berkowitz
Chief Medical Officer
 
Business Overview
Arvinas, Inc. is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The Company uses its PROTAC Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. It has four investigational clinical-stage programs: vepdegestrant (ARV-471) for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer; ARV-766 and bavdegalutamide for the treatment of men with metastatic castration-resistant prostate cancer, and ARV-102 for the treatment of patients with neurodegenerative disorders. Its product candidate, ARV-393, is designed to target the B-cell lymphoma 6, or BCL6 protein.
Financial Overview
For the fiscal year ended 31 December 2023, Arvinas Inc revenues decreased 40% to $78.5M. Net loss increased 30% to $367.3M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Research and development increase of 21% to $379.7M (expense), General and administrative increase of 26% to $100.3M (expense).
Employees: 445 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: $1,124M as of Dec 31, 2023
Annual revenue (TTM): $78.50M as of Dec 31, 2023
EBITDA (TTM): -$396.70M as of Dec 31, 2023
Net annual income (TTM): -$367.30M as of Dec 31, 2023
Free cash flow (TTM): -$350.70M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 68,308,405 as of Mar 31, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.